Jump to main content.


Bromobenzene Quickview (CASRN 108-86-1)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Bromobenzene

File First On-Line: 09/30/2009; Last Significant Revision: 09/30/2009

Category (section)
Status
Last Revised
Oral RfD Assessment On-line 09/30/2009
Inhalation RfC Assessment On-line 09/30/2009
Carcinogenicity Assessment On-line 09/30/2009
Synonyms
  • Bromobenzene
  • 108-86-1
  • 1-Bromobenzene
  • Bromobenzol
  • C6H5Br
  • Monobromobenzene
  • NCI-C55492
  • Phenyl bromide
  • UN2514
Bromobenzene Source Documents
Revision History
Date Section Description
09/30/2009 I., II. File first on-line.
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
UF RfD
Hepatocellular cytomegaly in male B6C3F1 mice BMDL10 : 24.1 mg/kg-day 3000 8 x10-3 mg/kg-day
(Chronic)

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page


Reference Concentration for Chronic Inhalation Exposure (RfC)

Critical Effect
Point of Departure*
UF RfC
Hepatocellular cytomegaly in female B6C3F1 mice BMCL10 (HEC): 63 mg/m3 1000 6x10-2 mg/m3
(Chronic)

* The Point of Departure listed serves as a basis from which the Inhalation RfC was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • Inadequate information to assess carcinogenic potential
  • Weight-of-Evidence Narrative:
    • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of bromobenzene.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Not Assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page


Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research


Local Navigation


Jump to main content.